表紙
市場調査レポート

Dr. Falk Pharma GmbH - 製品パイプライン分析

Dr. Falk Pharma GmbH - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 251662
出版日 ページ情報 英文 45 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
Dr. Falk Pharma GmbH - 製品パイプライン分析 Dr. Falk Pharma GmbH - Product Pipeline Review - 2015
出版日: 2015年05月29日 ページ情報: 英文 45 Pages
概要

Dr. Falk Pharma GmbH はドイツに本社を置く製薬企業で、炎症性腸疾患、憩室疾患、便秘、過敏性大腸炎、脂質代謝異常、肝臓疾患、胆石、亜鉛欠乏症といった消化器系疾患および血液系疾患の領域において治療薬の開発、製造、販売を行っています。

当レポートでは、Dr. Falk Pharma GmbH における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Dr. Falk Pharma GmbH の基本情報

  • Dr. Falk Pharma GmbH の概要
  • 主要情報
  • 企業情報

Dr. Falk Pharma GmbH :R&Dの概要

  • 主な治療範囲

Dr. Falk Pharma GmbH :パイプラインの分析

  • 開発段階別のパイプライン製品
  • 単剤製品
  • 併用療法モダリティ
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Dr. Falk Pharma GmbH :パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 第?相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第?相の製品/併用療法モダリティ
    • 第?相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
  • 開発段階が不明なパイプライン製品
    • 開発段階が不明な製品/併用療法モダリティ

Dr. Falk Pharma GmbH :薬剤プロファイル

  • budesonide
  • LT-02
  • mesalamine
  • rifamycin
  • norursodeoxycholic acid
  • udenafil
  • RhuDex
  • ZED-1227
  • ZED-101

Dr. Falk Pharma GmbH :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Dr. Falk Pharma GmbH :最近のパイプライン情報

Dr. Falk Pharma GmbH :開発休止中のプロジェクト

Dr. Falk Pharma GmbH :開発が中止されたパイプライン製品

Dr. Falk Pharma GmbH :企業理念

Dr. Falk Pharma GmbH :本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07127CDB

Summary

Global Markets Direct's, 'Dr. Falk Pharma GmbH - Product Pipeline Review - 2015', provides an overview of the Dr. Falk Pharma GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Dr. Falk Pharma GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Dr. Falk Pharma GmbH including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Dr. Falk Pharma GmbH's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Dr. Falk Pharma GmbH's pipeline products

Reasons to buy

  • Evaluate Dr. Falk Pharma GmbH's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Dr. Falk Pharma GmbH in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Dr. Falk Pharma GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Dr. Falk Pharma GmbH and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Dr. Falk Pharma GmbH
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Dr. Falk Pharma GmbH and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Dr. Falk Pharma GmbH Snapshot
    • Dr. Falk Pharma GmbH Overview
    • Key Information
    • Key Facts
  • Dr. Falk Pharma GmbH - Research and Development Overview
    • Key Therapeutic Areas
  • Dr. Falk Pharma GmbH - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Dr. Falk Pharma GmbH - Pipeline Products Glance
    • Dr. Falk Pharma GmbH - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Dr. Falk Pharma GmbH - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Dr. Falk Pharma GmbH - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
    • Dr. Falk Pharma GmbH - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Dr. Falk Pharma GmbH - Drug Profiles
    • budesonide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-02
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mesalamine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rifamycin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • norursodeoxycholic acid
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • udenafil
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RhuDex
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZED-1227
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZED-101
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Dr. Falk Pharma GmbH - Pipeline Analysis
    • Dr. Falk Pharma GmbH - Pipeline Products by Target
    • Dr. Falk Pharma GmbH - Pipeline Products by Route of Administration
    • Dr. Falk Pharma GmbH - Pipeline Products by Molecule Type
    • Dr. Falk Pharma GmbH - Pipeline Products by Mechanism of Action
  • Dr. Falk Pharma GmbH - Recent Pipeline Updates
  • Dr. Falk Pharma GmbH - Dormant Projects
  • Dr. Falk Pharma GmbH - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • CNDO-201
      • mesalamine
  • Dr. Falk Pharma GmbH - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Dr. Falk Pharma GmbH, Key Information
  • Dr. Falk Pharma GmbH, Key Facts
  • Dr. Falk Pharma GmbH - Pipeline by Indication, 2015
  • Dr. Falk Pharma GmbH - Pipeline by Stage of Development, 2015
  • Dr. Falk Pharma GmbH - Monotherapy Products in Pipeline, 2015
  • Dr. Falk Pharma GmbH - Partnered Products in Pipeline, 2015
  • Dr. Falk Pharma GmbH - Partnered Products/ Combination Treatment Modalities, 2015
  • Dr. Falk Pharma GmbH - Phase III, 2015
  • Dr. Falk Pharma GmbH - Phase II, 2015
  • Dr. Falk Pharma GmbH - Phase I, 2015
  • Dr. Falk Pharma GmbH - Preclinical, 2015
  • Dr. Falk Pharma GmbH - Unknown, 2015
  • Dr. Falk Pharma GmbH - Pipeline by Target, 2015
  • Dr. Falk Pharma GmbH - Pipeline by Route of Administration, 2015
  • Dr. Falk Pharma GmbH - Pipeline by Molecule Type, 2015
  • Dr. Falk Pharma GmbH - Pipeline Products by Mechanism of Action, 2015
  • Dr. Falk Pharma GmbH - Recent Pipeline Updates, 2015
  • Dr. Falk Pharma GmbH - Dormant Developmental Projects,2015
  • Dr. Falk Pharma GmbH - Discontinued Pipeline Products, 2015
  • Dr. Falk Pharma GmbH, Subsidiaries

List of Figures

  • Dr. Falk Pharma GmbH - Pipeline by Top 10 Indication, 2015
  • Dr. Falk Pharma GmbH - Pipeline by Stage of Development, 2015
  • Dr. Falk Pharma GmbH - Monotherapy Products in Pipeline, 2015
  • Dr. Falk Pharma GmbH - Partnered Products in Pipeline, 2015
  • Dr. Falk Pharma GmbH - Pipeline by Top 10 Target, 2015
  • Dr. Falk Pharma GmbH - Pipeline by Top 10 Route of Administration, 2015
  • Dr. Falk Pharma GmbH - Pipeline by Top 10 Molecule Type, 2015
  • Dr. Falk Pharma GmbH - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top